# Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects

> **NCT02492165** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 250 (actual)

## Conditions studied

- Japanese Encephalitis

## Interventions

- **BIOLOGICAL:** Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)
- **BIOLOGICAL:** Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)
- **BIOLOGICAL:** Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)
- **BIOLOGICAL:** Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)

## Key facts

- **NCT ID:** NCT02492165
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2016-03
- **Final completion:** 2016-06
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2022-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02492165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02492165, "Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02492165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*